Today: 8 June 2026
Browse Category

XETRA:BAYN 10 August 2025 - 6 May 2026

Bayer’s $2.45 Billion Perfuse Deal Puts Eye-Drug Pipeline Back in Focus

Bayer’s $2.45 Billion Perfuse Deal Puts Eye-Drug Pipeline Back in Focus

Bayer agreed to acquire Perfuse Therapeutics for up to $2.45 billion, including $300 million upfront, to gain access to a mid-stage eye-disease drug, PER-001. Eylea, Bayer’s top-selling eye drug, saw 2025 sales fall 5.9% to €3.11 billion amid generic competition. The deal awaits antitrust and shareholder approval. PER-001 is in Phase II trials for glaucoma and diabetic retinopathy.
6 May 2026
··
Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

Bayer’s Monsanto filed a lawsuit against Pfizer, BioNTech, and Moderna in Delaware federal court, alleging misuse of mRNA technology patents. Pfizer shares rose 0.9% to $25.67 in early trading after UBS began coverage with a Neutral rating and a $25 price target. Investors are watching for Pfizer’s Q4 and full-year 2025 results on February 3.
7 January 2026
····
German Stock Market Outlook Today (9 December 2025): DAX Futures Flat as Fed Cut Bets, Strong Data and M&A Shape the Open

German Stock Market Outlook Today (9 December 2025): DAX Futures Flat as Fed Cut Bets, Strong Data and M&A Shape the Open

Germany’s DAX closed Monday at 24,055, up 0.1%, staying above 24,000. Futures signal a flat or slightly lower open Tuesday. Investors await the U.S. Federal Reserve decision and eye strong German industrial data, though gains were driven by transport and defense orders. Bayer, Rheinmetall, and Deutsche Bank led Monday’s gainers.
9 December 2025
·····
DAX Today After the Bell: German Stock Market Edges Higher as Bayer and Kloeckner Rally – December 8, 2025

DAX Today After the Bell: German Stock Market Edges Higher as Bayer and Kloeckner Rally – December 8, 2025

Germany’s DAX 40 closed at 24,055.69 on Monday, up 0.11%, led by gains in Bayer (+4.70%) and Rheinmetall (+3.63%). Pharmaceuticals and defence stocks outperformed, while real estate lagged as Germany’s 30-year bond yield hit its highest since 2011. The VDAX volatility index fell 2.26% to a one-month low. Broader European markets were mixed, with the STOXX 600 down 0.1%.
8 December 2025
··
Bayer Aktie Soars After U.S. Roundup Breakthrough: Latest News, Analyst Forecasts and 2026 Outlook (4 December 2025)

Bayer Aktie Soars After U.S. Roundup Breakthrough: Latest News, Analyst Forecasts and 2026 Outlook (4 December 2025)

Bayer shares surged over 12% to a near two-year high on December 2, 2025, after the U.S. government urged the Supreme Court to review the company’s Roundup case. The stock briefly touched €35, marking its best trading day in 17 years. Despite the rally, Bayer’s five-year return remains about -40% due to ongoing litigation and restructuring.
4 December 2025
··
German Stock Market Today, December 4, 2025: DAX Climbs on Auto Rally and Fed Cut Hopes but Still Fails to Clear 24,000

German Stock Market Today, December 4, 2025: DAX Climbs on Auto Rally and Fed Cut Hopes but Still Fails to Clear 24,000

The DAX rose 0.8% to 23,877 in late morning trading Thursday, its highest in several sessions but still below the 24,000 mark for a third week. Gains were driven by optimism over possible U.S. rate cuts and a surge in European auto stocks after a bullish sector call. The MDAX, TecDAX, and SDAX also advanced. Mercedes-Benz and Porsche SE led sector gains.
4 December 2025
·····
German Stock Market Today, December 3, 2025: DAX Extends Rebound as Tech & Industrials Rise While PMI and Auto Sector Gloom Weigh

German Stock Market Today, December 3, 2025: DAX Extends Rebound as Tech & Industrials Rise While PMI and Auto Sector Gloom Weigh

Germany’s DAX 40 rose 0.3% to about 23,785 points by late morning Wednesday, extending its rebound after early December losses. Tech and industrial stocks led gains, echoing broader European strength, while fresh PMI data and weak auto sentiment underscored ongoing economic fragility. The MDAX was flat near 29,500. The TecDAX outperformed, up about 0.8%.
3 December 2025
German Stock Market Today, 2 December 2025: DAX Rebounds on Bayer Surge as Inflation Hits 2.2%

German Stock Market Today, 2 December 2025: DAX Rebounds on Bayer Surge as Inflation Hits 2.2%

Germany’s DAX 40 index closed up 0.8% at 23,780.07 on Tuesday, recovering part of Monday’s losses after Bayer surged up to 15% intraday. MDAX mid-caps rose 0.25%, while TecDAX slipped 0.16%. Eurozone November inflation came in at 2.2%, with Germany estimated at 2.6%, reinforcing expectations the ECB will hold rates steady. Market breadth was mixed, with several major stocks trading lower.
2 December 2025
··
Bayer Stock Rockets on U.S. Roundup Breakthrough – Is the 13% Rally the Start of a Trend?

Bayer Stock Rockets on U.S. Roundup Breakthrough – Is the 13% Rally the Start of a Trend?

Bayer shares jumped about 13% to a year high near €34–35 on Xetra after the U.S. Solicitor General backed Bayer’s request for Supreme Court review in the Roundup glyphosate case. The move follows renewed analyst upgrades and fresh pipeline news. Bayer says 132,000 of 197,000 Roundup claims have been resolved or declared ineligible as of October 2025.
2 December 2025
··
German Stock Market Today, 26 November 2025: DAX Extends Rally on Fed Rate‑Cut Bets and Ukraine Peace Hopes

German Stock Market Today, 26 November 2025: DAX Extends Rally on Fed Rate‑Cut Bets and Ukraine Peace Hopes

Germany’s DAX index closed at 23,531.62 on Wednesday, up 0.29%, marking a three-day rebound after hitting five-month lows last week. The MDAX rose 0.21% to 29,078.04, while the TecDAX slipped 0.11% to 3,493.06. Investors weighed weak German growth against expectations of U.S. rate cuts and signs of progress in Russia-Ukraine talks.
26 November 2025
··
Bayer Q3 2025: Adjusted Profit Jumps as Company Books €934m in Litigation Charges—Guidance Intact, Shares Rise

Bayer Q3 2025: Adjusted Profit Jumps as Company Books €934m in Litigation Charges—Guidance Intact, Shares Rise

Bayer reported a 20.8% rise in adjusted third-quarter EBITDA to €1.51 billion, beating analyst forecasts, as revenue reached €9.66 billion. The company booked €934 million in special charges, mostly for U.S. litigation, and raised its full-year special items estimate to up to €4 billion. Bayer kept its profit outlook unchanged. Shares rose as much as 5% intraday.
12 November 2025
···
BayWa Crisis: Cooperatives Take Over as Stock Soars on Rescue Plan

BayWa Crisis: Cooperatives Take Over as Stock Soars on Rescue Plan

BayWa AG’s main cooperative shareholders, BRB and RAI, have taken control and injected over €125 million, launching a rights issue to raise up to €77 million more. The company sold its RWA stake for €176 million and is restructuring after years of debt. BayWa stock rebounded on Oct 28, trading above its theoretical ex-rights price. The firm withdrew its 2025 profit forecast, citing market uncertainty.
28 October 2025
·
Breakthrough Cures, FDA Shake-Ups & Pharma Mega‑Deals: Global Health News Roundup (Aug 9–10, 2025)

Breakthrough Cures, FDA Shake-Ups & Pharma Mega‑Deals: Global Health News Roundup (Aug 9–10, 2025)

China researchers reported a hydrogel “smart” wound dressing that closed 90% of diabetic ulcers in mice within 12 days by delivering microRNA vesicles. The FDA approved Boehringer Ingelheim’s Hernexeos for advanced non-squamous NSCLC, with 75% of treated patients seeing tumors shrink or disappear. U.S. IV saline shortages ended as Baxter’s North Carolina plant resumed production after hurricane damage.
10 August 2025
······

Stock Market Today

  • June 2026 Watchlist: DBS, SGX, and Keppel DC REIT Show Strong Dividend Fundamentals
    June 8, 2026, 6:42 AM EDT. As June 2026 approaches, Singapore stocks DBS Group, Singapore Exchange (SGX), and Keppel DC REIT demonstrate robust fundamentals crucial for sustainable dividends. DBS posted Q1 2026 net income of S$2.93 billion and declared a 4.9% trailing dividend yield, supported by strong capital buffers and low loan defaults. SGX recorded a record half-year adjusted net profit of S$357.1 million and continues incrementally increasing dividends with a multi-asset model. These companies exemplify disciplined capital allocation, healthy cash flows, and strong earnings - vital for consistent dividend payments amid economic uncertainties.

Latest articles

American Airlines Stock Faces Fuel Question as United Merger Buzz Fades

American Airlines Stock Faces Fuel Question as United Merger Buzz Fades

8 June 2026
American Airlines shares closed at $13.50 Friday, up 1.5% on the day but down 5.9% from the prior Monday, as surging fuel costs and a rejected United merger overture keep the stock under industry stress; Brent crude jumped 4.47% to $97.15 a barrel, and American warned fuel expense could rise by over $4 billion this year, with second-quarter earnings guidance ranging from a 20-cent loss to a 20-cent profit.
Delta Back in Hong Kong, but United in Focus

Delta Back in Hong Kong, but United in Focus

8 June 2026
Delta Air Lines relaunched daily Los Angeles-Hong Kong flights, directly challenging United and Cathay Pacific amid high fuel costs and heavy competition; the move tests whether Delta’s premium cabins, cargo capacity, and LAX connections can drive growth as IATA slashes 2026 profit forecasts due to elevated fuel prices and regional disruptions.
FTSE 100 Dips While £2.7bn Takeover Drives London Headlines

FTSE 100 Dips While £2.7bn Takeover Drives London Headlines

8 June 2026
Tate & Lyle soared nearly 13% after Ingredion agreed to buy the British ingredients group for 595p per share in cash, valuing its equity at about £2.7 billion; meanwhile, the FTSE 100 slipped 0.28% as oil’s surge on renewed Middle East tensions lifted BP and Shell but pressured airlines and tech stocks, with higher bond yields adding further drag.
Air Liquide Shares Appear Down 10% as Bonus-Share Reset Takes Effect

Air Liquide Shares Appear Down 10% as Bonus-Share Reset Takes Effect

8 June 2026
Air Liquide shares fell 0.90% to €165.22 in Paris after a 1-for-10 bonus-share adjustment, with Eurex using a €183.40 closing price and a 0.90909091 adjustment factor; the move was technical, not a change in fundamentals, as investors await a June 9 shareholder meeting and July 28 first-half results.
Go toTop